Condition: Active Juvenile Psoriatic Arthritis · Sponsor: Amgen
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Landeskrankenhaus Bregenz | Bregenz, Austria | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Terminated |
| Centre Hospitalier Regional de la Citadelle | Liège, Belgium | Terminated |
| Ziekenhuis Netwerk Antwerpen Jan Palfijn | Merksem, Belgium | Terminated |
| Hospices Civils de Lyon Hopital Femme Mere Enfant | Bron, France | Recruiting |
| Hopital Jeanne de Flandre | Lille, France | Recruiting |
| Charite - Universitaetsmedizin Berlin, Campus Virchow | Berlin, Germany | Recruiting |
| Universitaetsklinikum Dresden | Dresden, Germany | Recruiting |
| An der Schoen Klinik Hamburg Eilbek | Hamburg, Germany | Recruiting |
| Asklepios Kinderklinik Sankt Augustin GmbH | Sankt Augustin, Germany | Completed |
| Agia Sofia Children Hospital | Athens, Greece | Recruiting |
| Attikon University General Hospital | Athens, Greece | Recruiting |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04804553